bioAffinity TechnologiesBIAF
BIAF
About: bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
Employees: 75
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
14% more funds holding
Funds holding: 14 [Q3] → 16 (+2) [Q4]
0.03% less ownership
Funds ownership: 3.47% [Q3] → 3.44% (-0.03%) [Q4]
49% less capital invested
Capital invested by funds: $973K [Q3] → $497K (-$475K) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for BIAF.
Financial journalist opinion
Based on 5 articles about BIAF published over the past 30 days
Neutral
Business Wire
3 days ago
bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies, Inc. (BIAF) releases financial results for 2024.
Neutral
Business Wire
1 week ago
Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies' CyPath Lung test uncovered a hidden second primary lung cancer in a patient who had been treated for lung cancer earlier.
Neutral
Business Wire
2 weeks ago
Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--In another case study, CyPath® Lung helped physicians identify and treat a recurrence of breast cancer in a high-risk patient.
Neutral
Business Wire
3 weeks ago
Physicians' Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Case studies highlight the benefit of CyPath Lung to both physicians and patients, including avoiding unnecessary invasive procedures.
Neutral
Business Wire
4 weeks ago
bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today announced strategic actions to cut $4 million in annual costs at its subsidiary CAP/CLIA pathology laboratory.
Neutral
PRNewsWire
1 month ago
WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million
JERSEY CITY, N.J. , Feb. 26, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that – bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) announced today it has closed its previously announced warrant exercise agreements with four existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 2,438,473 of the Company's shares of common stock (the "Existing Warrants").
Neutral
Business Wire
1 month ago
bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of warrant inducement transaction for aggregate gross proceeds of $1.4 million.
Neutral
PRNewsWire
1 month ago
WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million
JERSEY CITY, N.J. , Feb. 25, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 2,438,473 of the Company's shares of common stock (the "Existing Warrants").
Neutral
Business Wire
1 month ago
bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity has entered into warrant exercise agreements to exercise certain outstanding warrants for gross cash proceeds of $1.4 million.
Neutral
Zacks Investment Research
1 month ago
Zacks Initiates Coverage of bioAffinity With Neutral Recommendation
Discover why Zacks rates bioAffinity as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore BIAF's promising growth prospects and financial health amid market challenges.
Charts implemented using Lightweight Charts™